Novo Nordisk A/S (NYSE:NVO) Shares Sold by Toronto Dominion Bank

Toronto Dominion Bank cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 57.2% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 14,863 shares of the company's stock after selling 19,858 shares during the period. Toronto Dominion Bank's holdings in Novo Nordisk A/S were worth $1,770,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of NVO. 1620 Investment Advisors Inc. acquired a new stake in Novo Nordisk A/S in the 2nd quarter valued at $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at about $25,000. Gilliland Jeter Wealth Management LLC increased its stake in shares of Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company's stock worth $26,000 after purchasing an additional 120 shares in the last quarter. Daiwa Securities Group Inc. acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter worth about $28,000. Finally, Abound Wealth Management lifted its stake in Novo Nordisk A/S by 257.4% in the 2nd quarter. Abound Wealth Management now owns 218 shares of the company's stock valued at $31,000 after buying an additional 157 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analyst Ratings Changes

NVO has been the subject of several research reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating for the company in a research report on Thursday, October 17th. BNP Paribas upgraded Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. Finally, StockNews.com cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Friday. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of "Buy" and a consensus price target of $150.40.

Novo Nordisk A/S Trading Up 1.1 %

NYSE NVO traded up $1.12 on Monday, reaching $108.08. 5,344,558 shares of the company were exchanged, compared to its average volume of 4,534,407. Novo Nordisk A/S has a fifty-two week low of $98.52 and a fifty-two week high of $148.15. The stock has a market capitalization of $484.99 billion, a P/E ratio of 34.61, a price-to-earnings-growth ratio of 1.43 and a beta of 0.40. The business's fifty day moving average price is $110.59 and its 200 day moving average price is $126.17. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.